Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413391 | 0.86 | RAB9A (1.00) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL31435512 | 0.86 | RAB9A (1.00) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL31435488 | 0.83 | RAB9A (0.75) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL7010604 | 0.83 | TSHR (0.69) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL31435522 | 0.81 | RAB9A (0.66) | RAB9ATSHRL3MBTL1KMT2ASLC22A12 | |
| SCHEMBL29808604 | 0.80 | TSHR (0.53) | RAB9ATSHRL3MBTL1KMT2ASLC22A12 | |
| SCHEMBL9263968 | 0.80 | TSHR (0.75) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL31435524 | 0.80 | TSHR (0.70) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL28243567 | 0.80 | TSHR (0.69) | RAB9ATSHRL3MBTL1KMT2ANOTUM | |
| SCHEMBL8447109 | 0.77 | RAB9A (0.60) | RAB9ATSHRL3MBTL1KMT2ANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0901470-B1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6211223-B1 | BENZODIOXOL-5-YL-2-METHOXY-4-METHYLPHENYLSULFONYLAMINO-2-OXO ETHYL-1-METHYL-1HINDOLE-6-CARBOXYLIC ACID | PFIZER INC. | 2001-04-03 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
| WO-1999020623-A1 | INDOLE DERIVATIVE USEFUL AS ENDOTHELIN RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 1999-04-29 | — | — | WO | disclosed |
| EP-0901470-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | RAB9A 1408/4885TSHR 167/4885L3MBTL1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.